Halozyme Therapeutics, Inc. (HALO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 43.84 |
| Open | 44.08 |
| Bid | 43.12 x 400 |
| Ask | 43.17 x 400 |
| Day's range | 43.12 - 44.21 |
| 52-week range | 31.86 - 45.00 |
| Volume | |
| Avg. volume | 1,026,040 |
| Market cap | 5.492B |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | 17.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Halozyme to Participate in Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
- PR Newswire
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook.
- PR Newswire
Mahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
© 2024 Yahoo. All rights reserved.